Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Page 1
Dynamic changes in HLA-DR expression during short-term and long-term ibrutinib treatment in patients with chronic lymphocytic leukemia.
Manukyan G, Turcsanyi P, Mikulkova Z, Gabcova G, Urbanova R, Gajdos P, Smotkova Kraiczova V, Zehnalova S, Papajik T, Kriegova E. Manukyan G, et al. Among authors: gajdos p. Leuk Res. 2018 Sep;72:113-119. doi: 10.1016/j.leukres.2018.08.006. Epub 2018 Aug 10. Leuk Res. 2018. PMID: 30149317
There is the first evidence of changes in the kinetics of B cell antigen receptor (BCR) internalisation of neoplastic cells in chronic lymphocytic leukemia (CLL) after the short-term and long-term administration of ibrutinib. We aimed to assess the influence of shor …
There is the first evidence of changes in the kinetics of B cell antigen receptor (BCR) internalisation of neoplastic cells in chronic lymph …
Long-term results of treatment of childhood acute lymphoblastic leukemia in the Czech Republic.
Stary J, Jabali Y, Trka J, Hrusak O, Gajdos P, Hrstkova H, Sterba J, Blazek B, Hak J, Prochazkova D, Cerna Z, Smisek P, Sedlacek P, Vavra V, Mihal V, Hrodek O; Czech Pediatric Hematology working group. Stary J, et al. Among authors: gajdos p. Leukemia. 2010 Feb;24(2):425-8. doi: 10.1038/leu.2009.255. Epub 2009 Dec 17. Leukemia. 2010. PMID: 20016535 Clinical Trial. No abstract available.
The effects of short-term norepinephrine up-titration on hemodynamics in cardiogenic shock.
Rokyta R Jr, Tesařová J, Pechman V, Gajdos P, Kroužecký A. Rokyta R Jr, et al. Among authors: gajdos p. Physiol Res. 2010;59(3):373-378. doi: 10.33549/physiolres.931804. Epub 2009 Aug 12. Physiol Res. 2010. PMID: 19681659 Free article. Clinical Trial.
We observed no changes in lactate levels and mixed venous oxygen saturation. Our data suggest that short-term norepinephrine dose up-titration in cardiogenic shock patients treated or pretreated with inotropes was tolerated well by the diseased heart....
We observed no changes in lactate levels and mixed venous oxygen saturation. Our data suggest that short-term norepinephrine dose up- …
Intravenous immunoglobulin for myasthenia gravis.
Gajdos P, Chevret S, Toyka K. Gajdos P, et al. Cochrane Database Syst Rev. 2008 Jan 23;(1):CD002277. doi: 10.1002/14651858.CD002277.pub3. Cochrane Database Syst Rev. 2008. PMID: 18254004 Updated. Review.
MAIN RESULTS: We identified six randomised controlled trials, all of which investigated short-term benefit. A trial of IVIg compared with placebo including 51 patients provided evidence for the effectiveness of IVIg in myasthenia gravis worsening. ...
MAIN RESULTS: We identified six randomised controlled trials, all of which investigated short-term benefit. A trial of IVIg compared …
Intravenous immunoglobulin for myasthenia gravis.
Gajdos P, Chevret S, Toyka K. Gajdos P, et al. Cochrane Database Syst Rev. 2006 Apr 19;(2):CD002277. doi: 10.1002/14651858.CD002277.pub2. Cochrane Database Syst Rev. 2006. PMID: 16625559 Updated. Review.
MAIN RESULTS: We identified five randomised controlled trials, all of which investigated short-term benefit. The first study of 87 participants with exacerbation found no statistically significant difference between immunoglobulin and plasma exchange after two weeks. ...
MAIN RESULTS: We identified five randomised controlled trials, all of which investigated short-term benefit. The first study of 87 pa …
Corticosteroids for myasthenia gravis.
Schneider-Gold C, Gajdos P, Toyka KV, Hohlfeld RR. Schneider-Gold C, et al. Among authors: gajdos p. Cochrane Database Syst Rev. 2005 Apr 18;2005(2):CD002828. doi: 10.1002/14651858.CD002828.pub2. Cochrane Database Syst Rev. 2005. PMID: 15846640 Free PMC article. Review.
In the first (13 patients), the improvement was slightly greater in the prednisone group at six months. In the second (20 patients) which was a short-term trial, the improvement was significantly greater at two weeks. ...AUTHORS' CONCLUSIONS: Limited evidence from randomis …
In the first (13 patients), the improvement was slightly greater in the prednisone group at six months. In the second (20 patients) which wa …
Intravenous immunoglobulin for myasthenia gravis.
Gajdos P, Chevret S, Toyka K. Gajdos P, et al. Cochrane Database Syst Rev. 2003;(2):CD002277. doi: 10.1002/14651858.CD002277. Cochrane Database Syst Rev. 2003. PMID: 12804431 Updated. Review.
MAIN RESULTS: We identified four randomised controlled trials (147 participants in total), all investigating short-term benefit. In the first study of 87 people with myasthenia gravis exacerbation, comparing intravenous immunoglobulin and plasma exchange, there was no stat …
MAIN RESULTS: We identified four randomised controlled trials (147 participants in total), all investigating short-term benefit. In t …
Plasma exchange for myasthenia gravis.
Gajdos P, Chevret S, Toyka K. Gajdos P, et al. Cochrane Database Syst Rev. 2002;2002(4):CD002275. doi: 10.1002/14651858.CD002275. Cochrane Database Syst Rev. 2002. PMID: 12519572 Free PMC article. Review.
Non-randomised studies suggest that plasma exchange is beneficial in the short term. OBJECTIVES: To examine the efficacy of plasma exchange in the short and long term treatment of myasthenia gravis. ...There are no adequate randomised controlled trials to determine …
Non-randomised studies suggest that plasma exchange is beneficial in the short term. OBJECTIVES: To examine the efficacy of plasma ex …
[Contribution of intravenous immunoglobulins to the treatment of myasthenia].
Gajdos P. Gajdos P. Ann Med Interne (Paris). 2000 May;151 Suppl 1:1S30-4. Ann Med Interne (Paris). 2000. PMID: 10896986 Review. French.
More recently, high doses of immunoglobulins have been proposed and a controlled study has shown that they could be an alternative for the treatment of acute exacerbations of MG. Indication of immunoglobulin in the long term management of MG is not established....
More recently, high doses of immunoglobulins have been proposed and a controlled study has shown that they could be an alternative for the t …
Treatment of Hodgkin's disease in children with VAMP (vinblastine, adriamycin, methotrexate, prednisone) and VEPA (vinblastine, etoposide, prednisone, adriamycin).
Kavan P, Kabickova E, Koutecky J, McClain K, Gajdos P, Kodet R, Slavik Z, Tousovska K. Kavan P, et al. Among authors: gajdos p. Pediatr Hematol Oncol. 1999 Mar-Apr;16(2):141-8. doi: 10.1080/088800199277461. Pediatr Hematol Oncol. 1999. PMID: 10100274
Treatment of Hodgkin's disease in children should be directed at maximizing cures and minimizing the long-term effects of alkylating agents, anthracyclines, and bleomycin. ...
Treatment of Hodgkin's disease in children should be directed at maximizing cures and minimizing the long-term effects of alkylating …
18 results